Document Detail


High dose methotrexate with and without BCG therapy in advanced head and neck malignancy.
MedLine Citation:
PMID:  311679     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-three patients with advanced recurrent head and neck carcinoma were randomized to receive either high dose methotrexate with calcium leucovorin rescue (HDMTX) or HDMTX in combination with bacilli Calmette Guerin (HDMTX/BCG). An additional eight patients were treated with escalating doses of HDMTX ranging from 1 to 7 g of methotrexate. Of 12 patients receiving HDMTX, one complete response and two partial responses were noted. Of 11 patients in the HDMTX/BCG group, one complete response and two partial responses were observed. Only one partial response was noted in eight patients receiving escalating doses of the drug. Responses were brief and no significant difference in response duration was seen in any particular group. Toxicities in all groups were tolerable. BCG did not improve response rate, median duration of response, or median survival in these patients. Reported experiences with high dose methotrexate have been reviewed and again, responses to "high dose methotrexate" were found to be of brief duration. Despite acceptable toxicity, the brief duration of response and cost of such therapy raises serious question on the usefulness of chemoimmunotherapy utilizing high dose methotrexate with leucovorin rescue and BCG in the management of advanced recurrent carcinomas of the head and neck region.
Authors:
M Buechler; B Mukherji; W Chasin; L Nathanson
Related Documents :
9112499 - Long-term efficacy of intravesical bacillus calmette-guerin for carcinoma in situ: rela...
6555059 - Intratumoral bcg and corynebacterium parvum therapy of canine mammary tumours before ra...
8973689 - Bacillus calmette-guérin plus intravesical interferon alpha-2b in patients with superfi...
7460649 - Surgery, bcg immunotherapy, and multichemotherapy in t3 stage-3 bronchogenic carcinoma.
20723929 - Myopodin methylation is associated with clinical outcome in patients with t1g3 bladder ...
1502759 - Clinical value of pathologic changes after intravesical bcg therapy of superficial blad...
1913469 - Treatment of malignant leydig cell tumor.
7922999 - Transcatheter arterial embolization with or without cisplatin treatment of hepatocellul...
20589679 - Prognostic but not predictive role of platelet-derived growth factor receptors in patie...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cancer     Volume:  43     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1979 Mar 
Date Detail:
Created Date:  1979-06-26     Completed Date:  1979-06-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1095-100     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
BCG Vaccine / therapeutic use*
Carcinoma, Squamous Cell / drug therapy,  therapy*
Carcinoma, Transitional Cell / drug therapy,  therapy*
Head and Neck Neoplasms / drug therapy,  therapy*
Humans
Leucovorin / administration & dosage
Methotrexate / administration & dosage*,  adverse effects
Middle Aged
Stomatitis / chemically induced
Chemical
Reg. No./Substance:
0/BCG Vaccine; 58-05-9/Leucovorin; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sensitivity of hypothalamic sites to salicylate and prostaglandin.
Next Document:  Stimulation of resistance to tumor growth of athymic nude mice pretreated by combined local hyperthe...